The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients

Kenji Taketani, Eriko Tokunaga, Nami Yamashita, Kimihiro Tanaka, Sayuri Akiyoshi, Satoko Okada, Kouji Andou, Yasue Kimura, Hiroshi Saeki, Eiji Oki, Masaru Morita, Tetsuya Kusumoto, Yoshihiko Maehara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: It is important for patients to complete the planned hormone therapy to reduce both the recurrence and mortality rates of hormone receptor-positive breast cancer. We investigated the rates and factors related to the early discontinuation of adjuvant hormone therapy at our institution.

Methods: We identified 145 females prescribed adjuvant hormone therapy who were followed up for longer than 5 years. The rate of completing the planned hormone therapy and factors related to early discontinuation were examined. The relapse-free survival rate was examined between the completion group and the discontinuation group.

Results: The completion rate was 90.6 %. The primary reason for discontinuing hormone therapy within 5 years was side effects, such as arthritic pain. The primary factor related to early discontinuation was a significantly younger age. The relapse-free survival rate was significantly lower in the discontinuation group (p = 0.025).

Conclusions: More than 90 % of the patients completed the planned adjuvant hormone therapy, and early discontinuation was related to a shorter RFS. To improve the rate of the successful completion of adjuvant hormone therapy, it is important to provide supportive care to reduce the occurrence of side effects and to care for young females with a desire to become pregnant.

Original languageEnglish
Pages (from-to)1841-1846
Number of pages6
JournalSurgery Today
Volume44
Issue number10
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

Hormones
Breast Neoplasms
Therapeutics
Recurrence
Survival Rate
Arthritis
Pain
Mortality

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients. / Taketani, Kenji; Tokunaga, Eriko; Yamashita, Nami; Tanaka, Kimihiro; Akiyoshi, Sayuri; Okada, Satoko; Andou, Kouji; Kimura, Yasue; Saeki, Hiroshi; Oki, Eiji; Morita, Masaru; Kusumoto, Tetsuya; Maehara, Yoshihiko.

In: Surgery Today, Vol. 44, No. 10, 01.01.2013, p. 1841-1846.

Research output: Contribution to journalArticle

Taketani, K, Tokunaga, E, Yamashita, N, Tanaka, K, Akiyoshi, S, Okada, S, Andou, K, Kimura, Y, Saeki, H, Oki, E, Morita, M, Kusumoto, T & Maehara, Y 2013, 'The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients', Surgery Today, vol. 44, no. 10, pp. 1841-1846. https://doi.org/10.1007/s00595-013-0762-7
Taketani, Kenji ; Tokunaga, Eriko ; Yamashita, Nami ; Tanaka, Kimihiro ; Akiyoshi, Sayuri ; Okada, Satoko ; Andou, Kouji ; Kimura, Yasue ; Saeki, Hiroshi ; Oki, Eiji ; Morita, Masaru ; Kusumoto, Tetsuya ; Maehara, Yoshihiko. / The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients. In: Surgery Today. 2013 ; Vol. 44, No. 10. pp. 1841-1846.
@article{01c44278858848fd865d203d275660a9,
title = "The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients",
abstract = "Purpose: It is important for patients to complete the planned hormone therapy to reduce both the recurrence and mortality rates of hormone receptor-positive breast cancer. We investigated the rates and factors related to the early discontinuation of adjuvant hormone therapy at our institution.Methods: We identified 145 females prescribed adjuvant hormone therapy who were followed up for longer than 5 years. The rate of completing the planned hormone therapy and factors related to early discontinuation were examined. The relapse-free survival rate was examined between the completion group and the discontinuation group.Results: The completion rate was 90.6 {\%}. The primary reason for discontinuing hormone therapy within 5 years was side effects, such as arthritic pain. The primary factor related to early discontinuation was a significantly younger age. The relapse-free survival rate was significantly lower in the discontinuation group (p = 0.025).Conclusions: More than 90 {\%} of the patients completed the planned adjuvant hormone therapy, and early discontinuation was related to a shorter RFS. To improve the rate of the successful completion of adjuvant hormone therapy, it is important to provide supportive care to reduce the occurrence of side effects and to care for young females with a desire to become pregnant.",
author = "Kenji Taketani and Eriko Tokunaga and Nami Yamashita and Kimihiro Tanaka and Sayuri Akiyoshi and Satoko Okada and Kouji Andou and Yasue Kimura and Hiroshi Saeki and Eiji Oki and Masaru Morita and Tetsuya Kusumoto and Yoshihiko Maehara",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/s00595-013-0762-7",
language = "English",
volume = "44",
pages = "1841--1846",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "10",

}

TY - JOUR

T1 - The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients

AU - Taketani, Kenji

AU - Tokunaga, Eriko

AU - Yamashita, Nami

AU - Tanaka, Kimihiro

AU - Akiyoshi, Sayuri

AU - Okada, Satoko

AU - Andou, Kouji

AU - Kimura, Yasue

AU - Saeki, Hiroshi

AU - Oki, Eiji

AU - Morita, Masaru

AU - Kusumoto, Tetsuya

AU - Maehara, Yoshihiko

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Purpose: It is important for patients to complete the planned hormone therapy to reduce both the recurrence and mortality rates of hormone receptor-positive breast cancer. We investigated the rates and factors related to the early discontinuation of adjuvant hormone therapy at our institution.Methods: We identified 145 females prescribed adjuvant hormone therapy who were followed up for longer than 5 years. The rate of completing the planned hormone therapy and factors related to early discontinuation were examined. The relapse-free survival rate was examined between the completion group and the discontinuation group.Results: The completion rate was 90.6 %. The primary reason for discontinuing hormone therapy within 5 years was side effects, such as arthritic pain. The primary factor related to early discontinuation was a significantly younger age. The relapse-free survival rate was significantly lower in the discontinuation group (p = 0.025).Conclusions: More than 90 % of the patients completed the planned adjuvant hormone therapy, and early discontinuation was related to a shorter RFS. To improve the rate of the successful completion of adjuvant hormone therapy, it is important to provide supportive care to reduce the occurrence of side effects and to care for young females with a desire to become pregnant.

AB - Purpose: It is important for patients to complete the planned hormone therapy to reduce both the recurrence and mortality rates of hormone receptor-positive breast cancer. We investigated the rates and factors related to the early discontinuation of adjuvant hormone therapy at our institution.Methods: We identified 145 females prescribed adjuvant hormone therapy who were followed up for longer than 5 years. The rate of completing the planned hormone therapy and factors related to early discontinuation were examined. The relapse-free survival rate was examined between the completion group and the discontinuation group.Results: The completion rate was 90.6 %. The primary reason for discontinuing hormone therapy within 5 years was side effects, such as arthritic pain. The primary factor related to early discontinuation was a significantly younger age. The relapse-free survival rate was significantly lower in the discontinuation group (p = 0.025).Conclusions: More than 90 % of the patients completed the planned adjuvant hormone therapy, and early discontinuation was related to a shorter RFS. To improve the rate of the successful completion of adjuvant hormone therapy, it is important to provide supportive care to reduce the occurrence of side effects and to care for young females with a desire to become pregnant.

UR - http://www.scopus.com/inward/record.url?scp=84885509725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885509725&partnerID=8YFLogxK

U2 - 10.1007/s00595-013-0762-7

DO - 10.1007/s00595-013-0762-7

M3 - Article

C2 - 24142101

AN - SCOPUS:84885509725

VL - 44

SP - 1841

EP - 1846

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 10

ER -